Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date Sort descending | Expire Date | Purpose |
|---|---|---|---|---|---|
| Development of Animal Models and Related Biological Materials for Down Syndrome Research (R24 Clinical Trials Not-Allowed) | PAR-22-247 | OD | The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages grant applications aimed at developing, characterizing, or improving animal… More | ||
| The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) | RFA-OD-22-028 | ORWH | The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research applications… More | ||
| Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional) | RFA-HL-24-005 | NHLBI | The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 awardees for small grant support to expand their current research… More | ||
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) | PAR-23-029 | NICHD | The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are… More | ||
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | RFA-DA-24-007 | NIDA | oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of… More | ||
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | PAR-23-021 | NIDA | Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of… More | ||
| Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) | PAR-23-032 | NIAMS | Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not… More | ||
| Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01) | PAR-23-040 | ORIP | The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for… More | ||
| Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R24 Clinical Trials Not Allowed) | PAR-23-039 | ORIP | The Office of Research Infrastructure Programs (ORIP) encourages resource-related research grant applications aimed at developing broadly applicable technologies, tools, and resources for validating… More | ||
| Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | PAR-23-033 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product… More |